Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Early-stage pulmonary adenocarcinoma (T1N0M0): a clinical, radiological, surgical, and pathological correlation of 104 cases. The MD Anderson Cancer Center Experience.

Weissferdt A, Kalhor N, Marom EM, Benveniste MF, Godoy MC, Correa AM, Swisher SG, Moran CA.

Mod Pathol. 2013 Aug;26(8):1065-75. doi: 10.1038/modpathol.2013.33. Epub 2013 Mar 29.

2.

Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases.

Yoshizawa A, Motoi N, Riely GJ, Sima CS, Gerald WL, Kris MG, Park BJ, Rusch VW, Travis WD.

Mod Pathol. 2011 May;24(5):653-64. doi: 10.1038/modpathol.2010.232. Epub 2011 Jan 21.

3.

The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival.

Warth A, Muley T, Meister M, Stenzinger A, Thomas M, Schirmacher P, Schnabel PA, Budczies J, Hoffmann H, Weichert W.

J Clin Oncol. 2012 May 1;30(13):1438-46. doi: 10.1200/JCO.2011.37.2185. Epub 2012 Mar 5.

PMID:
22393100
4.

The prognostic role of pathologic invasive component size, excluding lepidic growth, in stage I lung adenocarcinoma.

Tsutani Y, Miyata Y, Mimae T, Kushitani K, Takeshima Y, Yoshimura M, Okada M.

J Thorac Cardiovasc Surg. 2013 Sep;146(3):580-5. doi: 10.1016/j.jtcvs.2013.04.032. Epub 2013 Jun 15.

5.

Prognostic value of the IASLC/ATS/ERS classification in stage I lung adenocarcinoma patients--based on a hospital study in China.

Song Z, Zhu H, Guo Z, Wu W, Sun W, Zhang Y.

Eur J Surg Oncol. 2013 Nov;39(11):1262-8. doi: 10.1016/j.ejso.2013.08.026. Epub 2013 Sep 11.

PMID:
24063970
6.

The International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society grading system has limited prognostic significance in advanced resected pulmonary adenocarcinoma.

Westaway DD, Toon CW, Farzin M, Sioson L, Watson N, Brady PW, Marshman D, Mathur MM, Gill AJ.

Pathology. 2013 Oct;45(6):553-8. doi: 10.1097/PAT.0b013e32836532ae.

PMID:
24018816
7.

Prognostic significance of adenocarcinoma in situ, minimally invasive adenocarcinoma, and nonmucinous lepidic predominant invasive adenocarcinoma of the lung in patients with stage I disease.

Kadota K, Villena-Vargas J, Yoshizawa A, Motoi N, Sima CS, Riely GJ, Rusch VW, Adusumilli PS, Travis WD.

Am J Surg Pathol. 2014 Apr;38(4):448-60. doi: 10.1097/PAS.0000000000000134.

8.

Prognostic value of the IASLC/ATS/ERS classification of lung adenocarcinoma in stage I disease of Japanese cases.

Woo T, Okudela K, Mitsui H, Tajiri M, Yamamoto T, Rino Y, Ohashi K, Masuda M.

Pathol Int. 2012 Dec;62(12):785-91. doi: 10.1111/pin.12016.

PMID:
23252867
9.

Histologic features are important prognostic indicators in early stages lung adenocarcinomas.

Yim J, Zhu LC, Chiriboga L, Watson HN, Goldberg JD, Moreira AL.

Mod Pathol. 2007 Feb;20(2):233-41. Epub 2006 Dec 22.

10.

Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma.

Yoshida T, Ishii G, Goto K, Yoh K, Niho S, Umemura S, Matsumoto S, Ohmatsu H, Nagai K, Ohe Y, Ochiai A.

J Cancer Res Clin Oncol. 2013 Oct;139(10):1691-700. doi: 10.1007/s00432-013-1495-0. Epub 2013 Aug 22.

PMID:
23974272
12.

Current readings: pathology, prognosis, and lung cancer.

Suh JH.

Semin Thorac Cardiovasc Surg. 2013 Spring;25(1):14-21. doi: 10.1053/j.semtcvs.2013.01.003. Review.

PMID:
23800525
13.

Relationship between lung adenocarcinoma histological subtype and patient prognosis.

Urer HN, Kocaturk CI, Gunluoglu MZ, Arda N, Bedirhan MA, Fener N, Dincer SI.

Ann Thorac Cardiovasc Surg. 2014;20(1):12-8. Epub 2013 Jan 31.

14.

Modified histologic classification as a prognostic factor in pulmonary adenocarcinoma.

Hwang I, Park KU, Kwon KY.

Int J Surg Pathol. 2014 May;22(3):212-20. doi: 10.1177/1066896914525230. Epub 2014 Mar 4.

PMID:
24599899
15.

Well-differentiated adenocarcinoma-bronchioloalveolar carcinoma-in situ adenocarcinoma: a conundrum.

Weissferdt A, Kalhor N, Moran CA.

Adv Anat Pathol. 2013 Sep;20(5):347-51. doi: 10.1097/PAP.0b013e3182a28aa1. Review.

PMID:
23939151
16.

Adenocarcinomas with prominent lepidic spread: retrospective review applying new classification of the American Thoracic Society.

Xu L, Tavora F, Battafarano R, Burke A.

Am J Surg Pathol. 2012 Feb;36(2):273-82. doi: 10.1097/PAS.0b013e31823b3eeb.

PMID:
22198010
17.

Distinctive histopathological features of lepidic growth predominant node-negative adenocarcinomas 3-5 cm in size.

Takahashi Y, Ishii G, Aokage K, Hishida T, Yoshida J, Nagai K.

Lung Cancer. 2013 Feb;79(2):118-24. doi: 10.1016/j.lungcan.2012.10.013. Epub 2012 Nov 21.

PMID:
23177278
18.

Adenocarcinoma in situ, minimally invasive adenocarcinoma, and invasive pulmonary adenocarcinoma--analysis of interobserver agreement, survival, radiographic characteristics, and gross pathology in 296 nodules.

Boland JM, Froemming AT, Wampfler JA, Maldonado F, Peikert T, Hyland C, de Andrade M, Aubry MC, Yang P, Yi ES.

Hum Pathol. 2016 May;51:41-50. doi: 10.1016/j.humpath.2015.12.010. Epub 2015 Dec 30.

PMID:
27067781
19.

Clinicopathological characteristics of subcentimeter adenocarcinomas of the lung.

Kato F, Hamasaki M, Miyake Y, Iwasaki A, Iwasaki H, Nabeshima K.

Lung Cancer. 2012 Sep;77(3):495-500. doi: 10.1016/j.lungcan.2012.05.109. Epub 2012 Jun 22.

PMID:
22727683
20.

New pathologic classification of lung cancer: relevance for clinical practice and clinical trials.

Travis WD, Brambilla E, Riely GJ.

J Clin Oncol. 2013 Mar 10;31(8):992-1001. doi: 10.1200/JCO.2012.46.9270. Epub 2013 Feb 11. Review.

PMID:
23401443

Supplemental Content

Support Center